HK1207321A1 - 涉及在金黃色葡萄球菌病期間中和凝固酶活性之抗體的組合物和方法 - Google Patents

涉及在金黃色葡萄球菌病期間中和凝固酶活性之抗體的組合物和方法

Info

Publication number
HK1207321A1
HK1207321A1 HK15108152.0A HK15108152A HK1207321A1 HK 1207321 A1 HK1207321 A1 HK 1207321A1 HK 15108152 A HK15108152 A HK 15108152A HK 1207321 A1 HK1207321 A1 HK 1207321A1
Authority
HK
Hong Kong
Prior art keywords
neutralize
antibodies
compositions
staphylococcus aureus
activity during
Prior art date
Application number
HK15108152.0A
Other languages
English (en)
Inventor
Molly Mcadow
Carla Emolo
Dominique M Missiakas
Olaf Schneewind
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Publication of HK1207321A1 publication Critical patent/HK1207321A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15108152.0A 2012-04-26 2015-08-24 涉及在金黃色葡萄球菌病期間中和凝固酶活性之抗體的組合物和方法 HK1207321A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261638797P 2012-04-26 2012-04-26
PCT/US2013/031927 WO2013162751A1 (en) 2012-04-26 2013-03-15 Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Publications (1)

Publication Number Publication Date
HK1207321A1 true HK1207321A1 (zh) 2016-01-29

Family

ID=49483735

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108152.0A HK1207321A1 (zh) 2012-04-26 2015-08-24 涉及在金黃色葡萄球菌病期間中和凝固酶活性之抗體的組合物和方法

Country Status (10)

Country Link
US (2) US9701738B2 (zh)
EP (1) EP2841101B1 (zh)
JP (2) JP6251730B2 (zh)
CN (1) CN104703622B (zh)
AU (1) AU2013252888B2 (zh)
BR (1) BR112014026808A2 (zh)
CA (1) CA2910320A1 (zh)
HK (1) HK1207321A1 (zh)
NZ (1) NZ702282A (zh)
WO (1) WO2013162751A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
NZ702285A (en) * 2012-04-26 2016-07-29 Univ Chicago Staphylococcal coagulase antigens and methods of their use
EP3096788B1 (en) * 2014-01-24 2019-07-31 Church, William, R. Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
AU2017218768B2 (en) * 2016-02-12 2022-03-31 Janssen Pharmaceuticals, Inc. Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2019003441A1 (ja) * 2017-06-30 2019-01-03 日本電気株式会社 予測装置、予測方法、予測プログラムが記録された記録媒体、及び、遺伝子推定装置

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4338298A (en) 1980-04-04 1982-07-06 Endowment And Research Foundation At Montana State University Vaccine for passive immunization against enteric colibacillosis and method of use
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
AU667533B2 (en) 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
EP0604662B1 (en) 1992-07-07 2008-06-18 Japan Tobacco Inc. Method of transforming monocotyledon
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
JP2952041B2 (ja) 1992-07-27 1999-09-20 パイオニア ハイ−ブレッド インターナショナル，インコーポレイテッド 培養ダイズ細胞のａｇｒｏｂａｃｔｅｒｉｕｍ媒介形質転換の改良法
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6770278B1 (en) 1994-12-02 2004-08-03 Central Biomedia, Inc. Methods of making and using immunoglobulin (Ig) compositions
US5548066A (en) 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
US5700928A (en) 1995-10-16 1997-12-23 Smithkline Beecham, P.L.C. Polynucleotide encoding saliva binding protein
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
CA2337966A1 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Vaccine against staphylococcus intoxication
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
JP4714342B2 (ja) 1998-08-31 2011-06-29 ザ プラヴアスト フエロウス アンド スカラース オブ ザ カレツヂ オブ ザ ハリー アンド アンデイヴアイデツド トリニテイ オブ クイーン エリザベス ニヤー ダブリン コアグラーゼ陰性スタフィロコカス菌に由来のポリペプチド及びポリヌクレオチド
US6355625B1 (en) 1998-09-14 2002-03-12 Nabi Compositions of β-glucans and specific IGIV
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
JP2002544488A (ja) 1999-05-07 2002-12-24 クアンタム ドット コーポレイション 半導体ナノクリスタルを用いて分析物を検出する方法
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
US20020169288A1 (en) 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
BRPI0515520A (pt) 2004-09-22 2008-07-29 Glaxosmithkline Biolog Sa composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
WO2006060728A2 (en) 2004-12-02 2006-06-08 University Of Chicago Methods and compositions involving lcrv proteins
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
EP2666784B1 (en) 2007-08-31 2017-04-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
CN102089005A (zh) 2008-05-12 2011-06-08 斯特罗克斯生物制药有限责任公司 金黄色葡萄球菌特异性抗体制剂
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
CA2739581A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US8370520B2 (en) 2008-11-24 2013-02-05 Juniper Networks, Inc. Adaptive network content delivery system
EP2414387B1 (en) * 2009-04-03 2015-12-16 University Of Chicago Compositions and methods related to protein a (spa) variants
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
CN103037885B (zh) 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides

Also Published As

Publication number Publication date
CN104703622B (zh) 2017-05-24
AU2013252888A1 (en) 2014-12-11
NZ702282A (en) 2016-07-29
US20170306004A1 (en) 2017-10-26
AU2013252888B2 (en) 2018-06-14
CA2910320A1 (en) 2013-10-31
US9701738B2 (en) 2017-07-11
EP2841101A1 (en) 2015-03-04
JP2018058871A (ja) 2018-04-12
WO2013162751A1 (en) 2013-10-31
JP2015515492A (ja) 2015-05-28
EP2841101A4 (en) 2016-02-24
BR112014026808A2 (pt) 2018-05-15
US20150368322A1 (en) 2015-12-24
CN104703622A (zh) 2015-06-10
EP2841101B1 (en) 2019-08-07
JP6251730B2 (ja) 2017-12-20

Similar Documents

Publication Publication Date Title
HRP20182017T1 (hr) Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe
HK1215452A1 (zh) 金黃色葡萄球菌表面決定簇的抗體
ZA201406026B (en) Compositions useful as animal litters
GB2535876B (en) Absorbent clumping animal litter compositions
ZA201407330B (en) Cross-reactive staphylococcus aureus antibody
EP2911507A4 (en) AGRICULTURAL PESTICIDE COMPOSITIONS
IL244936A0 (en) Cross-reactive staphylococcus aureus antibody sequences
HK1207321A1 (zh) 涉及在金黃色葡萄球菌病期間中和凝固酶活性之抗體的組合物和方法
EP2859791A4 (en) LITTER SAND FOR ANIMALS
EP2734229A4 (en) METHOD AND COMPOSITIONS FOR VACCINATING STAPHYLOCOCCUS AUREUS
EP2868192A4 (en) LITTER FOR ANIMALS
LT2814843T (lt) ŽMOGAUS MONOKLONINIAI ANTIKŪNAI, NEUTRALIZUOJANTYS IL-1ß
EP3416979A4 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY IN CASES OF GOLDEN STAPHYLOCOCCUS DISEASE
ZA201404038B (en) Plant disease control composition
ZA201404037B (en) Plant disease control composition
GB201217868D0 (en) Staphyolococcus aureus antigens
AU349671S (en) Animal litter puck
GB201108498D0 (en) Agricultural composition